Home > Resources > Whitepapers > Rheumatoid Arthritis - Old and New Approaches Shifting the Treatment Paradigm

Rheumatoid Arthritis - Old and New Approaches Shifting the Treatment Paradigm

October 19, 2018

Download your copy of Rheumatoid Arthritis: Old and New Approaches Shifting the Treatment Paradigm. Access the contents of this essential whitepaper from Informa Pharma Intelligence and explore the current and future outlook for rheumatoid arthritis (RA) treatments. Such treatments remain ineffective for the 33% of RA sufferers who are or become unresponsive to treatment, resulting in a high interest in RA drug development to address this unmet need in the marketplace.

Spotlight

SAP

SAP is a global software application vendor. SAP is the market leader in enterprise application software, helping companies of all sizes and in all industries run at their best: 77% of the world’s transaction revenue touches an SAP system. Our machine learning, Internet of Things (IoT), and advanced analytics technologies help turn customers’ businesses into intelligent enterprises. Our end-to-end suite of applications and services enables our customers to operate profitably, adapt continuously, and make a difference. With a global network of customers, partners, employees, and thought leaders, SAP helps the world run better and improves people’s lives.

OTHER WHITEPAPERS

Asia Pacific – Clinical trial landscape

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Optimizing Freeze-Thaw Processes for Cell and Gene Therapy Commercialization

whitePaper | June 23, 2022

Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.

6 Strategies to Stimulate Patient Engagementin Rehab Therapy

whitePaper | August 25, 2022

Patient engagement has become a measure of healthcare analytics that many in rehab therapy have sought to quantify.

Could DNA be the next big thing in data storage?

whitePaper | August 19, 2021

DNA storage technology is advancing rapidly. Atos is closely monitoring the development of this technology in the hope that future developments will make it a scalable, cost effective and crucially a decarbonized alternative to today’s carbon intensive technologies.